Impact of rosiglitazone meta-analysis on use of glucose-lowering medications

Open Medicine

Volumn 4, Issue 1, 2010, Pages

  Morrrrow, Richard L ^a   Carney, Greg ^a   Wright, James M ^a   Bassett, Ken ^a   Sutherland, Jenny ^a   Dormuth, Colin R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956047449     PISSN: None     EISSN: 19112092     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356(24):2457-2471.
2. FDA US Food and Drug Administration. FDA issues safety alert on Avandia [press release]; 2007 May 21. Available: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108917.htm (accessed 2010 Mar 2).
3. Health Canada endorsed important safety information on Avandia, Avandamet and Avandaryl: cardiac safety of Avandia (rosiglitazone maleate) [Dear Health Care Professional letter]. Ottawa (ON): Canadian Adverse Drug Reaction Monitoring Program, Health Canada; 2007 June 1. Available: www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2007/avandia_hpc-cps _4-eng.php (accessed 2010 Mar 2).
4. Shah BR, Juurlink DN, Austin PC, Mamdani MM. New use of rosiglitazone decreased following publication of a meta-analysis suggesting harm. Diabet Med 2008;25(7):871-874. 5.
5. Starner CI, Schafer JA, Heaton AH, Gleason PP. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. J Manag Care Pharm 2008;14(6):523-531.
6. George J, Hannah S, Lang CC. Thiazolidinediones and the influence of media adverse reporting on prescribing attitudes in practice (TZD-IMPACT) study. Cardiovasc Ther 2009;27(2):83-88.
7. Ministry of Health (British Columbia), PharmaCare. Coverage of thiazolidindiones (TZDs) for patients with Type II diabetes. BCPharmaCare Newsl 2005;5(6):1. Available: http://www.health.gov.bc.ca/pharmacare/newsletter/05006news.pdf (accessed 2010 Mar 2).
8. Ministry of Health (British Columbia), Pharmaceutical Services Division. Limited coverage program. BCPharmaCare Newsl 2007;7(5):7. Available: www.health.gov.bc.ca/pharme/newsletter/07-005news.pdf (accessed 2010 Mar 2).
9. Dormuth CR, Glynn RJ, Neumann P, Maclure M, Brookhart AM, Schneeweiss S. Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma. Clin Ther 2006;28(6):964-978; discussion 962-963.
10. Humphries KH, Rankin JM, Carere RG, Buller CE, Kiely FM, Spinelli JJ. Co-morbidity data in outcomes research: are clinical data derived from administrative databases a reliable alternative to chart review? J Clin Epidemiol 2000;53(4):343-349.
11. Steele LS, Glazier RH, Lin E, Evans M. Using administrative data to measure ambulatory mental health service provision in primary care. Med Care 2004;42(10):960-965.
12. Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med 2002;346(11):822-829.
13. Schneeweiss S, Soumerai SB, Maclure M, Dormuth C, Walker AM, Glynn RJ. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin Pharmacol Ther 2003;74(4):388-400.
14. Schneeweiss S, Maclure M, Dormuth CR, Glynn RJ, Canning C, Avorn J. A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences. Clin Pharmacol Ther 2006;79(4):379-388.
15. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002;27(4):299-309.
16. Shadish WR, Cook TD, Campbell DT. Quasi-experiments: interrupted time-series designs. In: Experimental and quasi-experimental designs for generalized causal inference. Boston (MA): Houghton Mifflin; 2002. p. 171-206.
17. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
18. Molenberghs G, Verbeke G. Generalized estimating equations. In: Models for discrete longitudinal data. New York: Springer Science + Business Media Inc; 2005. p. 151-187.
19. Ballinger GA. Using generalized estimating equations for longitudinal data analysis. Organ Res Methods 2004;7(2):127-150.
20. Smith T, Smith B. PROC GENMOD with GEE to analyze correlated outcomes data using SAS. Available: www.lexjansen.com/wuss/2006/tutorials/TUT-Smith.pdf (accessed 2010 Mar 2).
21. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001;154(9):854-864.
22. Romano PS, Roos LL, Jossis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993;46(10):1075-1079; discussion 1081-1090.
23. BC Ministry of Health Services. Frequently asked questions - full service family practice incentive program. Complex care fees - summary. Victoria (BC): The Ministry. Available: http://www.health.gov.bc.ca/msp/legislation/bcmaagree_faqs_fsfp.html (accessed 2010 Mar 2).
24. International Classification of Diseases, 9th rev, Clinical Modification, 6th ed. Washington (DC): US Department of Health and Human Services, Centers for Disease Control and Prevention, Centers for Medicare and Medicaid Services; 2003.
25. International Statistical Classification of Diseases and Related Health Problems, 10th rev, Version for 2007. Geneva: World Health Organization. 2006 May 4. Available: http://apps.who.int/classifications/apps/icd/icd10online/ (accessed 2010 Mar 2).
26. Bracken MB. Rosiglitazone and cardiovascular risk [letter]. N Engl J Med 2007;357(9):937-938.
27. Diamond GA, Kaul S. Rosiglitazone and cardiovascular risk [letter]. N Engl J Med 2007;357(9):938-939.
28. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298(10):1189-1195.
29. GlaxoSmithKline clinical study register. Avandia cardiovascular event modeling project. Study no. ZM2005/00181/01. Available: http://www.gsk-clinicalstudyregister.com/files/pdf/3104 .pdf (accessed 2010 Mar 2).
30. Nissen SE, Wolski K. Rosiglitazone and cardiovascular risk [letter]. N Engl J Med 2007;357(9):939-940.
31. Rosiglitazone no longer recommended [editorial]. Lancet 2008;372(9649):1520.
32. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32(1):193-203.
33. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373(9681):2125-2135.
34. Psaty BM, Furberg CD. The record on rosiglitazone and the risk of myocardial infarction [editorial]. N Engl J Med 2007;357(1):67-69.
35. Retnakaran R, Zinman B. Thiazolidinediones and clinical outcomes in type 2 diabetes. Lancet 2009;373(9681):2088-2090.
36. Winkelmayer WC, Setoguchi S, Levin R, Solomon DH. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 2008;168(21):2368-2375.
37. Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 2009;339:b2942.
38. Health Canada endorsed important safety information on Avandia, Avandamet and Avandaryl: increased incidence of fractures in female patients who received long-term treatment with AVANDIA (rosiglitazone maleate) tablets for type 2 diabetes mellitus [Dear Health Care Professionals letter]. Ottawa (ON): Canadian Adverse Drug Reaction Monitoring Program, Health Canada; 2007 Feb 23. Available: www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2007/avandia_hpc-cps_3-eng.php (accessed 2010 Mar 2).
39. Health Canada endorsed important safety information on ACTOS (pioglitazone hydrochloride): increased incidence of fractures in female patients who received long-term treatment with Actos (pioglitazone hydrochloride) tablets for type 2 diabetes mellitus. [Dear Health Care Professionals letter]. Ottawa (ON): Canadian Adverse Drug Reaction Monitoring Program, Health Canada; 2007 Apr 18. Available: www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2007/actos_hpc-cps_2-eng.php (accessed 2010 Mar 2).
40. GlaxoSmithKline. Clinical trial observation of an increased incidence of fractures in female patients who received long-term treatment with Avandia® (rosiglitazone maleate) tablets for type 2 diabetes mellitus. 2007 Feb. Available: http://www. fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ UCM153903.pdf (accessed 2010 Mar 2).
41. Takeda Pharmaceuticals. Observation of an increased incidence of fractures in female patients who received long-term treatment with Actos® (pioglitazone HCI) tablets for Type 2 diabetes mellitus. 2007 Mar. Available: http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ UCM153896.pdf (accessed 2010 Mar 2).
42. FDA US Food and Drug Administration. Manufacturers of some diabetes drugs to strengthen warning on heart failure risk: companies will include boxed warning on drug label [press release]. 2007 Aug 14. Available: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2007/ucm108966.htm (accessed 2010 Mar 2).
43. Health Canada endorsed important safety information on rosiglitazone (AVANDIA, AVANDAMET and AVANDARYL): new restrictions on the use of rosiglitazone products due to cardiac safety concerns (AVANDIA, AVANDAMET and AVANDARYL) [Dear Health Care Professional letter]. Ottawa (ON): Canadian Adverse Drug Reaction Monitoring Program, Health Canada; 2007 Nov 1. Available: www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2007/avandia_hpc-cps_5-eng.php (accessed 2010 Mar 2).